Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ORMP | US
0.03
1.30%
Healthcare
Biotechnology
30/06/2024
21/10/2024
2.35
2.30
2.37
2.30
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2 an orally ingestible insulin capsule which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801 Phase 2 oral insulin capsule for non-alcoholic steatohepatitis a progressive liver diseases; and ORMD-0901 an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
View LessStrength based on increasing price with high volume
Value Stock (Price to Book < 3)
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
37.8%1 month
32.7%3 months
46.7%6 months
51.0%4.54
-
0.53
-
-
0.52
2.86
-
-12.65M
95.60M
95.60M
-
-
-
-100.00
12.70
3.47
0.92
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.19
Range1M
0.28
Range3M
0.65
Rel. volume
1.25
Price X volume
246.28K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| INmune Bio Inc | INMB | Biotechnology | 5.18 | 102.73M | 1.37% | n/a | 14.65% |
| Clearside Biomedical Inc | CLSD | Biotechnology | 1.32 | 101.31M | 14.78% | n/a | -168.27% |
| Cue Biopharma Inc | CUE | Biotechnology | 1.68 | 101.15M | 38.84% | n/a | 52.09% |
| Marinus Pharmaceuticals Inc | MRNS | Biotechnology | 1.82 | 100.25M | -1.62% | n/a | -202.54% |
| Regulus Therapeutics Inc | RGLS | Biotechnology | 1.5 | 98.20M | -4.46% | n/a | 1.45% |
| Prelude Therapeutics Incorporated | PRLD | Biotechnology | 1.78 | 97.94M | -6.32% | n/a | 9.99% |
| Genenta Science S.p.A | GNTA | Biotechnology | 5.35 | 97.46M | -2.73% | n/a | 0.00% |
| Agenus Inc | AGEN | Biotechnology | 4.5 | 97.07M | -2.60% | n/a | -170.56% |
| Coherus BioSciences Inc | CHRS | Biotechnology | 0.8758 | 96.93M | -0.80% | n/a | -354.71% |
| Oncolytics Biotech Inc. (USA) | ONCY | Biotechnology | 1.26 | 96.84M | -6.67% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.87 | 94.40M | 1.83% | 5.16 | 19.82% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 14.22 | 89.04M | -1.80% | 14.48 | 7.10% |
| Urban One Inc | UONEK | Broadcasting - Radio | 1.01 | 53.54M | -3.35% | n/a | 268.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.44 | 20.47M | 4.19% | n/a | 204.46% |
| ILAG | ILAG | Building Products & Equipment | 1 | 18.06M | -2.91% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.52 | - | Par |
| Ent. to Revenue | 2.86 | - | Cheaper |
| PE Ratio | 4.54 | 41.03 | Cheaper |
| Price to Book | 0.53 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 46.69 | - | Lower Risk |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 95.60M | - | Emerging |